The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...

New research finds older women achieve the best results with weight loss injections – thanks to consistent tracking and ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...

Several cancers are linked to obesity, so researchers are now looking into whether popular weight loss drugs could reduce ...

We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...